Janice Mehnert, MD
Enriched profileDirector, Melanoma and Cutaneous Medical Oncology; Professor of Medicine at NYU Grossman School of Medicine; Associate Director for Clinical Research, Perlmutter Cancer Center · NYU Langone Health
Janice Mehnert is Director, Melanoma and Cutaneous Medical Oncology; Professor of Medicine at NYU Grossman School of Medicine; Associate Director for Clinical Research, Perlmutter Cancer Center at NYU Langone Health. OpenAlex indexes 327 publications with 13,770 citations (h-index 55); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Janice Mehnert is Director, Melanoma and Cutaneous Medical Oncology at NYU Langone Health. The public record shows 327 publications with 13,770 citations (h-index 55), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 13 companies, 4 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2020 · Cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 118.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Co-teacher
seminar for developing competitive ASCO Young Investigator Award applications at NYU Grossman School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Principal Investigator
Keynote-028 trial contributing to FDA approval of pembrolizumab for small cell lung cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Sponsor: NYU Langone Health
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Sponsor: Nested Therapeutics, Inc
Industry payments
Updated 18 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202511 payments$11,711openpaymentsdata.cms.gov ↗
- Immunocore LimitedProgram year20258 payments
- Merck Sharp & Dohme LLCProgram year20254 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Corticosteroid100%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
4 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- K12 Training for Clinical and Translational Oncology Researchers
New York University School of Medicine
FY2026$809,988K12CA270377 - Clinical Protocol and Data Management
New York University School of Medicine
FY2026$391,425P30CA016087 - “Promoting a Culture Of Innovation, Mentorship, and Clinical Investigation in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D
New York University School of Medicine
FY2026$110,706R50CA282100
Congress activity
Updated 18 Oct 2026
103 congress contributions (2007–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.
Pigment cell & melanoma research
Clinical Trial2018
Most-cited works
by citation count (OpenAlex)- 01Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyArticle1,725 citations2020
- 02
- 03Autophagy, Metabolism, and CancerArticle664 citations2015
- 04Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersArticle642 citations2015
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/janice-mehnert-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
blog.ecog-acrin.org/news-in-brief-december-2021
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.ecog-acrin.org ↗ - Other
connect.medicalnewstoday.com/provider/dr-janice-mehnert-1962617472
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connect.medicalnewstoday.com ↗ - Other
nyulangone.org/doctors/1962617472/janice-mehnert
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
ECOG-ACRIN Melanoma Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Past Chair
Melanoma and Skin Cancer Scientific Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - Member
Steering Committee of the Society for Melanoma Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - Member
Investigational Drug Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Medicine
Robert Wood Johnson Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - Regional Phase I Clinical Program Director
Rutgers Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Kevin Brown, MD
National Cancer Institute